Lenz Therapeutics, Inc. income statement

In fiscal 2025, Lenz Therapeutics, Inc. reported revenue of $19.1m, operating income of −$91.1m (a -477.5% margin) and net income of −$82.1m, or −$2.85 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Lenz Therapeutics, Inc.: income statement, annual
Fiscal year	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	0	19	21
Cost of revenue	0	0	—
Gross profit	0	19	—
Research and development	30	19	4
Selling, general and administrative	29	91	152
Operating income	−59	−91	−136
Income before tax	−50	−82	—
Income tax	0	1	—
Net income	−50	−82	−126
Diluted EPS	−$2.34	−$2.85	−$4.12
Diluted shares (average)	21m	29m	31m
EBITDA	−59	−91	−135

US$ millions unless shown otherwise. Fiscal quarters.

Lenz Therapeutics, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	0	0	0	5	13	2	2	5
Cost of revenue	—	—	0	0	—	—	1	0
Gross profit	—	—	0	5	—	—	1	5
Research and development	6	6	6	9	4	0	0	0
Selling, general and administrative	6	9	11	13	28	40	45	39
Operating income	−13	−15	−17	−17	−19	−38	−44	−34
Income before tax	−10	−13	—	−14	−17	−36	—	−32
Income tax	0	0	—	1	0	0	—	0
Net income	−10	−13	−15	−15	−17	−36	−41	−32
Diluted EPS	−$0.38	−$0.41	−$0.53	−$0.53	−$0.59	−$1.20	−$1.32	−$1.02
EBITDA	−13	−15	−17	−17	−19	−38	−44	−34

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: JANX vs LENZ LENZ vs SCYX CELU vs LENZ

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lenz Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lenz Therapeutics, Inc.